|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We discovered that c-MET activation and AXIN1 mutations occur concomitantly in ~3%-5% of human HCC samples.
|
30737831 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Identification of a malignant stemlike subtype of HCC may offer patients with a dismal prognosis a potential targeted therapy using c-MET and Wnt pathway inhibitors.
|
21737452 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The hepatocyte growth factor receptor c-Met has been shown to play an important role in the pathogenesis of HCC, but the influence of c-Met expression on the clinical course of HCC remains to be fully elucidated.
|
31846974 |
2020 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma.
|
24992910 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.
|
23593387 |
2013 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
c-Met receptor tyrosine kinase has been regarded as a promising therapeutic target for hepatocellular carcinoma (HCC).
|
25058462 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi.
|
30573522 |
2019 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The ARQ 197-215 study randomized patients to tivantinib or placebo and pre-specified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib in hepatocellular carcinoma (HCC).
|
28122337 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
STMN1 upregulation mediates HCC and hepatic stellate cells crosstalk to aggravate cancer through triggering MET pathway.
|
31785057 |
2020 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We propose that context-specific processing of c-Met protein is implicated in HCC progression in stressful microenvironments.
|
22418436 |
2012 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progression.
|
25607934 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We explored the contribution of MET pathway to the enhanced HCC invasion and metastasis by VEGF signaling inhibition, and investigated the antitumor effects of NZ001, a novel dual inhibitor of MET and VEGFR2, in HCC.
|
29712569 |
2018 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to determine the clinical significance of MET and RON expression on long-term survival and recurrence after curative resection in a large cohort of hepatocellular carcinoma (HCC) patients.
|
25874493 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
|
9096589 |
1997 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC.
|
23295441 |
2013 |
|
Liver carcinoma
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)-mediated phosphorylation of the MET kinase in hepatocellular carcinoma cells, whereas enforced expression of C1GALT1 enhanced MET phosphorylation.
|
23832667 |
2013 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In addition, c-MET expression levels did not affect RFS or HCC-specific survival. c-MET expression was weakly correlated with c-MET copy number variation (r=0.255, p<0.001), but more than half of all patients with c-MET overexpression had a neutral c-MET copy number. c-MET protein expression was very weakly but significantly positively correlated with its mRNA expression (r=0.199, p=0.002).
|
24222167 |
2013 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Expression of c-met was determined by Northern-blot hybridization of a specific probe (human met proto-oncogene) in 18 tumoral and nontumoral liver samples obtained in 18 cirrhotic patients with hepatocellular carcinoma submitted to surgical treatment.
|
8276372 |
1994 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
This study investigated "repurposed" [<sup>18</sup>F]FACBC for PET imaging of primary liver cancer such as hepatocellular carcinoma (HCC) in comparison with [<sup>11</sup>C]Met.
|
31119488 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib.
|
29625879 |
2018 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
HCC with high MET expression showed improved PFS with approximately 3-fold increase in PFS (8.1 vs. 2.8 months) relative to low MET expression.
|
31142504 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In sum, our findings reveal a novel regulatory signaling cascade, the HULC/miR-2052/MET axis, which could potentially be exploited for therapeutic benefits in the treatment of HCC.
|
31645479 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepatocellular carcinoma (HCC) cell line HCA-1 and in immune-competent and immunodeficient mice with subcutaneous tumors grown from this cell line.
|
30711629 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Interestingly, highly proliferative tumors also demonstrated high MET expression, likely explaining better therapeutic response of MET-high HCC patients to tivantinib.<b>Conclusions:</b> Tivantinib acts as an antimitotic compound, and cell proliferation markers are the best predictors of its antitumor efficacy in cell lines.
|
28246274 |
2017 |